by heshamhamed | Feb 25, 2025 | News
The scientific discovery behind Adoram has been published in the Journal of Medicinal Chemistry (ACS Publications). In the original article “Discovery of the First Efficacious Adenosine 2A Receptor Negative Allosteric Modulators for High Adenosine Cancer...
by heshamhamed | Feb 25, 2025 | News
Adoram Therapeutics_Press release_20250225Download
by heshamhamed | Feb 25, 2025 | News
We are thrilled to announce that Adoram Therapeutics has received generous funding from FIF! A heartfelt thank you to the FIF, Fongit and the members of the selection committee representing various stakeholders from the canton of Geneva for believing in our vision and...
by heshamhamed | Feb 7, 2025 | News
Adoram was invited to pitch as one of the top 10 Health Track finalists at the global SouthSummit24 startup competition. Co-CEO David Pejoski presented a company update at La Nave in Madrid, where over 18,000 participants met to network and showcase their deeptech...
by heshamhamed | Jan 31, 2025 | News
David pitching at Japan Roadshow, in October 2024. Last year saw Adoram being well represented by its co-CEO David Pejoski and Hesham Hamed on various national and international events, pitching on the following Biotech events: SwissBiotech Association CEO Forum, Jan...
